Capsid & Tail
Loading issues…
- Phages to treat our most vulnerable patientsShould phage therapy be considered for pregnant women? This week, Dr. Lucy Furfaro introduces the field of perinatal phage research.
- Collaboration leads to phage therapy successThe first case of phage therapy in Israel shows how patients can benefit from collaborations between academia, medicine, military and biotech.
- Using zebrafish to model phage therapyThis week, we highlight a useful new animal model for the phage therapy community.
- How do we commercialize phage therapy? A full recap of Phage Futures 2019We attended Phage Futures 2019 at the end of January, and now present our full recap of the event.
- What's it like to help with phage crowdsourcing?To understand what it's like to take part in phage crowdsourcing, we interviewed five labs who've contributed phages on behalf of a patient.
- Studying phage-host coevolution in the labHow is phage-host coevolution studied in the lab, and what can it tell us?
- Incentives for phage drug developmentA look into government incentives for antimicrobial development, and how they apply to phage therapeutic development.
- Alternatives to patenting phages: trade secrecyIn past issues, we covered what it means to patent something & whether patenting works for phages. In this issue, we dive into an alternative to patenting: trade secrecy.
- Impressions of Phage Futures 2019This week, we attended Phage Futures Congress 2019, which we found to be a huge success!
- Patenting phages, part II: What makes something patentable?Simply having a patent on something doesn’t actually protect your invention. That patent has to actually hold up in court. How is this determined, and what kind of chance do phages stand?
- Breaking down phage patentabilityYou may have heard through the grapevine that “phages can’t be patented”, but several phage patents exist, and biotech and pharma are investing in phage-based therapeutics. What’s the deal?
- Where in the world (and how) can I get phage therapy?People are starting to ask questions about phage therapy. We need your help to put together an FAQ. Do they qualify? How can they get it, and where do they get it?
- New reporting standards for uncultivated viral genomesHave you submitted genome sequences for phages that haven’t been cultured yet? Here’s what you should report if and when you do.
- Capsids in the classroom (and a challenge for 2019)This week, we’re sharing insights from our experience talking to middle school kids about phages, phage therapy, and Phage Directory.
- Tweaking the microbiome with phages: Q&A with BiomX CBO Assaf OronThis week, we bring you a Q&A with BiomX CBO Assaf Oron.
- Belgium’s new brand of phage therapyThis week, we explore Belgium's unique new way of treating patients with phages...
- Special issue: An update on our current phage crowdsourcing campaignTo provide a window into what happens during a phage hunt, we're devoting this issue to showing some of what's happened over the last three weeks. We've put together an infographic to help illustrate how labs across the globe have come…
- Happy (American) Thanksgiving!We’re incredibly humbled by all the wonderful feedback and for your help in spreading the word about Capsid & Tail and Phage Directory. Thank you!!
- Reflecting on our first yearFor this week’s issue, we’d like to reflect on our first year as Phage Directory. We’re one year old this week!
- Phage crowdsourcingThis is the second post in a series on how patients are being treated with phages outside of traditional clinical trials.